Item 9 Labs Corp Nears Completion of Facility Expansion to More Than Double Cultivation Output Capacity
SCOTTSDALE, Ariz., March 12, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, today announced its Arizona expansion has neared completion. The 10,000 square-foot construction will more than double output capacity with increased cultivation manufacturing space and an infusion kitchen.
The addition is the second phase of a national expansion plan, a three-tiered initiative that commenced in 2018. City inspections have been scheduled and an Approval to Operate request for inspection has been submitted.
This expansion encompasses our surrounding community
stated CEO Sara Gullickson.
It gives Item 9 Labs the opportunity to grow our staff numbers and provide sound and stable employment for approximately 20 local individuals
Item 9 Labs cultivation and processing facility will now total 20,000 square-feet and feature four flowering rooms each at 1,500 square-feet, a 1,000 square-foot vegetative room, and a 550 square-foot infusion kitchen.
The additions we have made will allow us to enter the medical cannabis market with new formulations and product suites
explained Christopher Wolven, COO at Item 9 Labs.
Headquartered in Southern Arizona, Item 9 Labs owns and operates 50 acres and is one of the largest properties in the U.S. zoned to grow and cultivate medical marijuana. The Company is renowned for its award-winning flower, diverse concentrate products, and proprietary THC and CBD-derived delivery systems, including an Intra-Nasal device and Apollo Vape Pen and Pod System.
Item 9 Labs will commence the third phase of its expansion in November 2019. For information visit Item9LabsCorp.com.
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of todays modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.